Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta 1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients

被引:388
作者
Fukaura, H
Kent, SC
Pietrusewicz, MJ
Khoury, SJ
Weiner, HL
Hafler, DA
机构
[1] BRIGHAM & WOMENS HOSP, DEPT NEUROL, CTR NEUROL DIS, BOSTON, MA USA
[2] HARVARD UNIV, SCH MED, BOSTON, MA USA
关键词
demyelination; oral tolerance; autoantigen; regulatory cytokines;
D O I
10.1172/JCI118779
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Oral administration of antigen is a long recognized method of inducing systemic immune tolerance, In animals with experimental autoimmune disease, a major mechanism of oral tolerance triggered by oral administration of antigen involves the induction of regulatory T cells that mediate active suppression by secreting the cytokine TGF-beta 1. Multiple sclerosis (MS) is a presumed T cell-mediated Th1 type autoimmune disease, Here, we investigated whether in MS patients oral myelin treatment, containing both myelin basic protein (MBP) and proteolipid protein (PLP), induced antigen specific MBP or PLP reactive T cells that either secreted IL-4, TGF-beta 1, or alternatively did Th1 type sensitization occur as measured by IFN-gamma secretion, Specifically, 4,860 short-term T cell lines were generated to either MBP, PLP, or tetanus toroid (TT) from 34 relapsing-remitting MS patients: 17 orally treated with bovine myelin daily for a minimum of 2 yr as compared to 17 nontreated patients. We found a marked increase in the relative frequencies of both MBP and PLP specific TGF-beta 1-secreting T cell lines in the myelin treated MS patients as compared to non-treated MS patients (MBP P < 0.001, PLP P < 0.003). In contrast, no change in the frequency of MBP or PLP specific IFN-gamma of TT specific TGF-beta 1 secreting T cells were observed. These results suggest that the oral administration of antigens generates antigen specific TGF-beta 1 secreting Th3 cells of presumed mucosal origin that represent a distinct Lineage of T cells, Since antigen-specific TGF-beta 1 secreting cells localize to the target organ and then suppress inflammation in the local microenvironment, oral tolerization with self antigens may provide a therapeutic approach for the treatment of cell-mediated autoimmune disease which does not depend upon knowledge of the antigen specificity of the original T cell clone triggering the autoimmune cascade.
引用
收藏
页码:70 / 77
页数:8
相关论文
共 36 条
[1]   SUPPRESSION OF EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS BY THE ORAL-ADMINISTRATION OF MYELIN BASIC-PROTEIN [J].
BITAR, DM ;
WHITACRE, CC .
CELLULAR IMMUNOLOGY, 1988, 112 (02) :364-370
[2]   FATTY-ACID COMPOSITION OF HUMAN MYELIN PROTEOLIPID PROTEIN IN PEROXISOMAL DISORDERS [J].
BIZZOZERO, OA ;
ZUNIGA, G ;
LEES, MB .
JOURNAL OF NEUROCHEMISTRY, 1991, 56 (03) :872-878
[3]  
CHASE MW, 1946, P SOC EXP BIOL MED, V61, P257
[4]   REGULATORY T-CELL CLONES INDUCED BY ORAL TOLERANCE - SUPPRESSION OF AUTOIMMUNE ENCEPHALOMYELITIS [J].
CHEN, YH ;
KUCHROO, VK ;
INOBE, J ;
HAFLER, DA ;
WEINER, HL .
SCIENCE, 1994, 265 (5176) :1237-1240
[5]   Oral tolerance in myelin basic protein T-cell receptor transgenic mice: Suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells [J].
Chen, YH ;
Inobe, J ;
Kuchroo, VK ;
Baron, JL ;
Janeway, CA ;
Weiner, HL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (01) :388-391
[6]   PERIPHERAL DELETION OF ANTIGEN-REACTIVE T-CELLS IN ORAL TOLERANCE [J].
CHEN, YH ;
INOBE, J ;
MARKS, R ;
GONNELLA, P ;
KUCHROO, VK ;
WEINER, HL .
NATURE, 1995, 376 (6536) :177-180
[7]  
CHOU FCH, 1976, J BIOL CHEM, V251, P2671
[8]   INDUCTION OF ANERGY OR ACTIVE SUPPRESSION FOLLOWING ORAL TOLERANCE IS DETERMINED BY ANTIGEN DOSAGE [J].
FRIEDMAN, A ;
WEINER, HL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (14) :6688-6692
[9]   IMMUNOLOGICAL MECHANISMS AND THERAPY IN MULTIPLE-SCLEROSIS [J].
HAFLER, DA ;
WEINER, HL .
IMMUNOLOGICAL REVIEWS, 1995, 144 :75-107
[10]  
HIGGINS PJ, 1988, J IMMUNOL, V140, P440